These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 80469)

  • 41. On the relationship between Lp(a) lipoprotein, "sinking pre-beta-lipoprotein" and inherited hyper-beta-lipoproteinaemia.
    Heiberg A; Berg K
    Clin Genet; 1974; 5(2):144-56. PubMed ID: 4364245
    [No Abstract]   [Full Text] [Related]  

  • 42. Humoral mechanisms of atherogenesis.
    Batuca JR; Amaral MC; Alves JD
    Ann N Y Acad Sci; 2009 Sep; 1173():401-8. PubMed ID: 19758179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epitope expression in purified and lipid-bound forms of human apoprotein A-I.
    James RW; Pometta D
    Adv Exp Med Biol; 1987; 210():31-5. PubMed ID: 2438912
    [No Abstract]   [Full Text] [Related]  

  • 44. [Polymorphism of mink serum alpha2-lipoproteins].
    Titok TG; Romanov LM
    Tsitol Genet; 1977; 11(1):44-8. PubMed ID: 70873
    [No Abstract]   [Full Text] [Related]  

  • 45. Management of hyperlipidemias.
    Murphy BF
    JAMA; 1974 Dec 23-30; 230(12):1683-91. PubMed ID: 4373590
    [No Abstract]   [Full Text] [Related]  

  • 46. The immunogenicity of modified lipoproteins.
    Lopes-Virella MF; Thorpe SR; Derrick MB; Chassereau C; Virella G
    Ann N Y Acad Sci; 2005 Jun; 1043():367-78. PubMed ID: 16037258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a specific monoclonal antibody 9F5-3a and the development of assay system for oxidized HDL.
    Nakajima T; Sakagishi Y; Katahira T; Nagata A; Kuwae T; Nakamura H; Inoue I; Takahashi K; Katayama S; Komoda T
    Biochem Biophys Res Commun; 1995 Dec; 217(2):407-11. PubMed ID: 7503715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients.
    Kopprasch S; Bornstein SR; Schwarz PE; Bergmann S; Julius U; Graessler J
    Atheroscler Suppl; 2013 Jan; 14(1):157-60. PubMed ID: 23357158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of modified lipoproteins in diabetic macroangiopathy.
    Witztum JL
    Diabetes; 1997 Sep; 46 Suppl 2():S112-4. PubMed ID: 9285511
    [No Abstract]   [Full Text] [Related]  

  • 50. DNA polymorphisms at the lipoprotein lipase gene and their association with quantitative variation in plasma high-density lipoproteins and triacylglycerides.
    Mitchell RJ; Earl L; Bray P; Fripp YJ; Williams J
    Hum Biol; 1994 Jun; 66(3):383-97. PubMed ID: 8026810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.
    Eisenberg S; Bilheimer DW; Levy RI; Lindgren FT
    Biochim Biophys Acta; 1973 Dec; 326(3):361-77. PubMed ID: 4359865
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR; Yeshurun D; Jackson RL; Gotto AM
    Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
    [No Abstract]   [Full Text] [Related]  

  • 53. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis.
    Fornasieri A; Perugini C; Seccia M; Napodano P; D'Amico G; Bellomo G
    J Nephrol; 2002; 15(4):349-57. PubMed ID: 12243363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP.
    Lauer ME; Graff-Meyer A; Rufer AC; Maugeais C; von der Mark E; Matile H; D'Arcy B; Magg C; Ringler P; Müller SA; Scherer S; Dernick G; Thoma R; Hennig M; Niesor EJ; Stahlberg H
    J Struct Biol; 2016 May; 194(2):191-8. PubMed ID: 26876146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Immune response to plasma lipoproteins induced by C-reactive protein].
    Nazarov PG; Petrov IV; Kositskaia LS; Berestovaia LK; Denisenko AD
    Biull Eksp Biol Med; 1998 Jul; 126(7):76-9. PubMed ID: 9777204
    [No Abstract]   [Full Text] [Related]  

  • 56. Metabolic fate of chylomicron phospholipids and apoproteins in the rat.
    Tall AR; Green PH; Glickman RM; Riley JW
    J Clin Invest; 1979 Oct; 64(4):977-89. PubMed ID: 225354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Myeloma and hyperlipemia. IV. Nature of the specific anti-lipoprotein activity].
    Beaumont JL; Poullin MF; Jacotot B; Beaumont V
    Nouv Rev Fr Hematol; 1967; 7(4):481-98. PubMed ID: 4228342
    [No Abstract]   [Full Text] [Related]  

  • 58. The use of nitroblue tetrazolium prestaining of serum lipoproteins on polyacrylamide disc electrophoresis.
    Segal AW; Putman D; Levi AJ; Lewis B
    Clin Chim Acta; 1974 Jun; 53(3):361-7. PubMed ID: 4367870
    [No Abstract]   [Full Text] [Related]  

  • 59. [A myeloma gamma A-globulin with a specific anti-lipoprotein activity. The anti-Pg autoantibody].
    Beaumont JL
    C R Acad Hebd Seances Acad Sci D; 1966 Dec; 263(25):2046-9. PubMed ID: 4167660
    [No Abstract]   [Full Text] [Related]  

  • 60. [Regulation of low (LDL) and high (HDL) density lipoprotein binding sites on fibroblasts of metabolically healthy and homozygote familial hypercholesteremic (HFH) subjects].
    Koschinsky T; Carew TE; Steinberg D
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():378-81. PubMed ID: 206052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.